Your browser doesn't support javascript.
loading
Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study.
Ozdemir, Nesligul; Aktas, Burak Y; Gulmez, Ahmet; Inkaya, Ahmet C; Bayraktar-Ekincioglu, Aygin; Kilickap, Saadettin; Unal, Serhat.
Afiliación
  • Ozdemir N; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey. nesliozdmr@hotmail.com.
  • Aktas BY; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
  • Gulmez A; Department of Medical Oncology, Inonu University Faculty of Medicine, Malatya, Turkey.
  • Inkaya AC; Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Bayraktar-Ekincioglu A; Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Ankara, Turkey.
  • Kilickap S; Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.
  • Unal S; Department of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Support Care Cancer ; 31(3): 194, 2023 Mar 01.
Article en En | MEDLINE | ID: mdl-36856870
ABSTRACT

PURPOSE:

This study aimed to evaluate clinical pharmacist's contribution to the pneumococcal vaccination rate by providing education to cancer patients in hospital settings.

METHODS:

This study was conducted in 2 tertiary-care hospitals' medical oncology outpatient clinics. Patients over 18 years of age and diagnosed with cancer for less than 2 years, in remission stage, and have not previously received the pneumococcal vaccine were included. Patients were randomized to intervention and control groups. The intervention group was provided vaccination education and recommended to receive the PCV13 vaccine. The control group received routine care. Patients' knowledge about pneumonia/pneumococcal vaccine, Vaccine Attitude Examination Scale (VAX) score, and vaccination rates were evaluated at baseline and 3 months after the education.

RESULTS:

A total of 235 patients (intervention 117, control 118) were included. The mean age ± SD was 57.86 ± 11.88 years in the control and 60.68 ± 11.18 years in the intervention groups. The numbers of correct answers about pneumonia/pneumococcal vaccine (p = 0.482) and VAX scores (p = 0.244) of the groups were similar at baseline. After the intervention, the median (IQR) number of correct answers in intervention group [10(3)] was higher than control group [8(4)] (p < 0.001). After the education, the total VAX score (mean ± SD) was less in intervention group (33.09 ± 7.018) than the control group (36.07 ± 6.548) (p = 0.007). Three months after the education, 20.2% of the patients in the intervention and 6.1% in the control groups were vaccinated with pneumococcal vaccine (p = 0.003).

CONCLUSIONS:

The pneumococcal vaccination rate in cancer patients has increased significantly by the education provided by a clinical pharmacist in hospital settings.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Farmacéuticos / Neoplasias Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Farmacéuticos / Neoplasias Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article